

**CEO
CFO**


Inergetics

Issue:
January 14, 2011

All rights reserved!
ceocointerviews.com

The Most Powerful Name In Corporate News and Information

Inergetics, Inc., (NRTI) is well positioned for immediate growth. Its Surgex® Sports Nutritional Supplement is currently on the market being used by the military and professional and amateur elite athletes. Its Resurgex™ Select oncology supplement about to begin clinical trials and worldwide distribution will definitely improve the quality of life in cancer patients.

**Healthcare
Drug Related Products
(NRTI-OTC: BB)**

Inergetics, Inc.

**205 Robin Street, Suite 222
Paramus, NJ 07652
Phone: 908-604-2500**



**Mark C. Mirken
President, CEO & Chairman**

BIO:

Mr. Mirken has been Inergetics' President & Chief Executive Officer since August 2008. Since joining the Company, Mr. Mirken has successfully transitioned its major revenue sources from a powdered formulation to Ready-to-Drink (RTD) formulations of its Resurgex® and Sur-

gex® nutritional supplements and established contractual relationships with major pharmaceutical and international distributors. Additionally, Mark has increased shareholder value by overseeing the financial restructuring of the Company and enhancing the Company's intellectual property portfolio via the creation of proprietary manufacturing formulas. (Would "proprietary product formulas or formulations" be better here rather than "manufacturing"?)

Previously, Mr. Mirken served as President & COO of TurboChef Technologies, Inc. (Nasdaq: OVEN) a world leader in technology, equipment and services for high-speed food preparation from 2000-2005. While with TurboChef, he had global P&L accountability for the entire company, conceived and executed business strategies, steered the direction of development and growth and managed all aspects of operations including R&D, engineering, product development, new business development, sales, marketing, branding, manufacturing, investor relations, PR, media affairs, and major/global channels and the management of such large and prestigious accounts as Subway, Starbucks, BP and HMS Host.

Also while with TurboChef, Mr. Mirken mentored and led a core management team of ten executives (including CFO, CTO and Director of Manufacturing in China), directed a twenty-four person global sales force, and provided indirect oversight to a global workforce of over one hundred people. Mark was responsible for creating the strategic alliance with Coca-Cola and engineering the

Coke/ Subway agreement. During his tenure, Mr. Mirken enhanced shareholder value by over 1,000%.

Prior to TurboChef, he was affiliated with Vista Research Inc., a Standard & Poors business unit, where he consulted for The Middleby Corp. (NASDAQ: MIDD), Pequot Capital, Fidelity Family of Funds and KKR on various acquisitions. Mr. Mirken earned a Bachelor of Science degree from the University of North Carolina and a J.D. from the University of North Carolina School of Law.

Company Profile:

Inergetics, Inc. is a leading developer of nutritional supplements for the Clinical Health and Sports Nutritional Supplement markets. The Company has established a line of Resurgex products consisting of proprietary nutritional formulas that are used by a wide range of clinical patients and consumers. Resurgex™ products provide comprehensive nutritional support for actively treated cancer patients as well as those in post-treatment care and elderly members of the assisted living community. Inergetics has also developed Surgex® sports nutrition formula to meet the nutritional needs of professional, Olympic, and amateur elite athletes that experience post-workout symptoms such as fatigue, loss of lean muscle, oxidative stress and reduced immune function.

**Interview conducted by:
Lynn Fosse, Senior Editor**

CEOCFO: Mr. Mirken, what is the focus at Inergetics today?

Mr. Mirken: Inergetics is basically an intellectual property company in the nutritional space, which is extremely unique. We have three channels of business in which our products exist. First is long-term care with our Essential and Essential Plus product line, second is our Resurgex™ Select, which is our oncology product line and the third is Surgex™, which is our sports nutritional line. Surgex are the only independently clinically validated products in the nutritional space using GliSODin®, which is superoxide dismutase and that really separates us by leaps and bounds from all other so-called functional beverages and products.

CEOCFO: Would you explain the business side?

Mr. Mirken: The business side is that we own and have developed all of the formulas, which are patented and protect us in those categories. We have the ability and have a contract manufacturer for all of our products with the Garden State Nutritionals division of Vitaquest, in Caldwell New Jersey. They are one of the largest manufacturers in the world of specialized nutritional products.

CEOCFO: Would you tell us a bit more about your Surgex product and how it differs from what else is available?

Mr. Mirken: The nutritional supplement in the sports space is a very unique product for athletes at various levels. The product approved by the Banned Substance Control Group, and used from high school athletics all the way through the Olympics. The product is sold in the United States as well as internationally. So if you were looking at products such as Gatorade, or Muscle Milk, it would be products like that, which are somewhat similar, but not competitive with Surgex®. We have independent trials at Rutgers University where the product was used for the Rutgers football team and the women's soccer team, and the clinical trials established the products' superiority above all other products.

CEOCFO: What does the Surgex® do for athletes?

Mr. Mirken: Our Surgex® product basically does four things for the athlete. First, you have to address the nutritional needs of the athlete. Secondly, what the product has the ability to do is reduce lactic acid. So it gives you the ability to get ready to perform better, and provides significant amounts of energy with such nutritional components as Co-Q10, Ribose and MCTs. All of these components provide energy to the athlete instead of stimulating the athlete with caffeine or other stimulants that provide a quick surge of energy, but then a crash. It enables the athlete to perform better specifically by releasing proteins that help build

Inergetics is now moving into its revenue phase on a domestic and international basis. The company has expended approximately \$30 to \$40 million in the development of its products, owns all of the intellectual property around them, has the ability and will leverage that intellectual property into the development of other products and other channels. We have had almost \$70 million net operating loss, but that operating loss will shield all of the taxable income at least for the next three or four years from any taxes, so the gross pretty much becomes net. In addition, we have some exceptional strategic alliances with some billion-dollar drug companies. We are starting distributorships in Europe and Asia in the ASEAN countries, with our recent FDA approval. - Mark C. Mirken

lean body mass without overloading the body with excess proteins and then recovery, which is the most important part with any athlete, because then it allows you to perform better tomorrow. We do that through the use of GliSODin®, which is the superoxide dismutase that allows the neutralization of cell damaging free-radical molecules. The product has been sold in the NBA, the NFL, and the PGA. In addition, it has a very high level of acceptance for the high school athlete where the kids are taking the wrong products, banned products, banned substances, and losing their eligibility to play in high school and subsequently in college.

CEOCFO: Is your Surgex® product well-known in the athletic community?

Mr. Mirken: Our Surgex® product is just becoming very well-known in the athletic community. We have recently brought on Joe Theismann, who was a great NFL quarterback and is currently a world-known NFL commentator. He is not only an investor in the company, but he is one of our spokes people. The product will be distributed on a global basis, and the distribution platforms will range from a DTC (direct to consumer) model, to sponsoring major events. We will be utilizing various channels of distribution including the gym channel through major gym facilities, sporting goods stores, specialty stores, and mass market. So the

product has basically been incubated for approximately two years while the trials were being finished. We have invested somewhere upwards of \$30 million in the development of this and the oncology product and we are now going into the commercialization phase, looking to generate significant revenue in 2011.

CEOCFO: How do you get people to understand the unique features?

Mr. Mirken: It is that the consumer and our demographic is a very intelligent, very well read and voracious internet user. However, we were published in two peer journals, the “Strength and Conditioning

Coaches Journal”, and the “Journal for Applied Physiology.” All of our medical data has now been accepted at peer review levels so when this hits the marketplace, which it just has and people read that this is available, they can see the proven trials. In addition, they can see the professionals who evangelize the product. We know that the product is significantly different at every level and we know that the product, based on the reception we are getting, will commercialize and turn into revenue in the upcoming quarters. The company I ran before I ran Inergetics, which is called TurboChef Technologies, Inc. (Nasdaq: OVEN), also went through the same procedure and we went

from a \$0.27 stock to a \$27.00 stock in a period of a year and a half.

CEO CFO: So you and your team know how to do this?

Mr. Mirken: My team and I definitely know how to do this. We just ask people to consider the credentials of the team. For example, our Chief Science Officer, Mr. Carl Germano, has impeccable credentials. He has actually written seven books and is about to launch his eighth book called the *Misled Athlete* that basically tells the problems today that the athlete is faced with because the athlete is not knowledgeable about these areas. However, they will be soon.

CEO CFO: Regarding your expected worldwide distribution, are there any particular areas you are focusing on, are there countries or regions that are more receptive, and what are your plans?

Mr. Mirken: We have distribution in Canada for our oncology product, which is Resurgex Select™. Our partner is Ferring Pharmaceuticals and they are a billion dollar drug company. They selected us to go to market with Firmagon, which was their billion-dollar blockbuster prostate cancer drug. We just signed a transaction with companies in the Philippines and the ASEAN countries, which surround the Philippines. In addition, we have significant distribution in Greece and we will expand that distribution to Europe over the next twelve to eighteen months. The product is widely acclaimed in Greece, through some of the leading oncologists in that country. We just see a very rapid spread of the oncology product and the sports product over the next twelve to 24 months.

CEO CFO: What are the basic differences in the products?

Mr. Mirken: The oncology product is unique in its nutritional composition. We have announced that it is going into trial in St. Jude's Hospital, which is the largest pediatric oncology hospital in the world, and Columbia Presbyterian. They are taking their product into trial within the next sixty days.

CEO CFO: Development is typically expensive; what is the financial picture like for Inergetics today?

Mr. Mirken: Development is very expensive, and in today's environment that is always for any company an issue in the capital raising area. However, we actually have the development behind us. The company has gone through a capital restructuring and transferred almost 70% of its outstanding debt to equity. Now we see the completion of that part of our financial picture and moving forward into the revenue and commercialization part of the picture and providing shareholder value.

CEO CFO: Do you do much investor outreach?

Mr. Mirken: We have an internal IR/PR function. We do investor outreach on a selective basis. We have a PR firm, which we retain to take us and our product into various media formats, we will be on a major television program in the first quarter, for both products.

CEO CFO: Producing safe products seems to be a focus for Inergetics, such as avoiding the use of high fructose corn syrup and corn oil. Would you explain the dangers of these products and how it separates you from the competition?

Mr. Mirken: Most of the carbohydrates we eat are made up of chains of glucose. When glucose enters the bloodstream, the body releases insulin to help regulate it. Fructose, on the other hand, is processed in the liver. To greatly simplify the situation: When too much fructose enters the liver, the liver can't process it all fast enough for the body to use as sugar. Instead, it starts making fats from the fructose and sending them off into the bloodstream as triglycerides. In addition, fructose leads to problematic events that increase your risk of diabetes and internal stress. These are potentially bad for at least several reasons:

- High blood triglycerides are a risk factor for heart disease. A study done at the University of Texas Southwestern Medical Center and published in the *Journal of Nutrition* found that the body rapidly converts fructose into fat. The liver decides how the body will use dietary sugars; when it encounters glucose, it decides whether it will

store it, burn it as energy, or convert it to triglycerides. When fructose enters the body, it completely bypasses this process and floods the bloodstream, quickly converting to fat. This fact also was reported in a presentation "Fructose linked to fatty artery deposits and increases heart risk factors" at the *67th American Diabetes Association Scientific Sessions, Chicago* "Fructose Increases Heart Risk Factors -- and Weight" by Kimber Stanhope, et al

- Fructose contains mercury – a known toxin. As if the problems of fructose increasing fatty deposits and increasing your risk of diabetes weren't bad enough, a report in the *Journal of Environmental Health* showed that almost half of tested samples of commercial high-fructose corn syrup contains the neurotoxin mercury, which is a result of the production process. This is especially troubling considering the amount of HFCS that our children consume.
- There is growing evidence that excess fructose consumption may facilitate **insulin resistance**, and eventually **type 2 diabetes**. In one study, patients who consumed drinks sweetened with fructose had an increase in abdominal fat, elevated bad cholesterol and insulin resistance, compared with those who drank glucose-sweetened drinks as reported by Peter J. Havel, M.D., of the University of California Davis, and colleagues reported online in the *Journal of Clinical Investigation*.
- Fructose increase oxidative stress in the body. In a study "A dose of fructose induces oxidative stress during endurance and strength exercise" published in the Oct 2009 edition of the *Journal of sports science*, investigators have reported that the addition of fructose to a pre-exercise

glucose supplement triggers oxidative stress.

CEOCFO: In closing, why should potential investors pick Inergetics out of the crowd?

Mr. Mirken: Inergetics is now moving into its revenue phase on a domestic and international basis. The company has expended approximately \$30 to \$40 million in the development of its products,

owns all of the intellectual property around them, has the ability and will leverage that intellectual property into the development of other products and other channels. We have had almost \$70 million net operating loss, but that operating loss will shield all of the taxable income at least for the next three or four years from any taxes, so the gross pretty much becomes net. In addition, we have some exceptional strategic alliances with some

billion-dollar drug companies. We are starting distributorships in Europe and Asia in the ASEAN countries, with our recent FDA approval. Further, we have straightened out the balance sheet. So that would give any investor, and I am an investor, great comfort in knowing that the problems of the past reflected in today's stock will be gone and the opportunity is clearly in front of us.



Inergetics, Inc.
205 Robin Street, Suite 222
Paramus, NJ 07652
Phone: 908-604-2500